Epistem‘s molecular diagnostic (Genedrive) has achieved 100% accuracy in detecting a genotype relevant to Hepatitis – an important proof of concept for this field device.
Located in Manchester (UK), Epistem has a market cap of €130,000 and 29 employees.
One of its research areas is molecular diagnostics, under which it developed Genedrive. This device can make test for genotypes (gene variants) in under 60 minutes, enabling low cost and high sensitivity diagnostics at the point of care – such as clinics.
Now Epistem has announced that one of its available assays (for the Hepatitis C virus) has been validated in an independent clinical trial conducted by the Institut Pasteur and Hôpital Cochin (Paris).
The assay only requires a mouth swab, and can distinguish between different genotypes of the IL28B gene – which codes for a cell-signalling protein (cytokine) involved in the immune response to viral infection.
Certain variants (single nucleoside polymorphisms –